Today we speak of Sanyang, which is our luxuries package, and many of whom have a pathological diagnosis such as ERPR positive, her2+fish positive, or three plus this, which we all consider to be hormonal receptor positive, two hormone receptors and her2 positive, which is characterized by multiple channels that stimulate one of the growth of the tumor, but which is now more clearly analysed by medicine, so there is a treatment for different hormonal receptor positives. So, if it’s Sanyang, if it’s clearly diagnosed as Sanyang from the early puncture, what’s the order of our treatment? And what about our new aid cycle, about six to eight cycles, where a chemotherapy drug and anti-vomit target are used together. And in the early hours of the new reinforcements, we’re often double-targeting, and that’s the traverse. In other words, the two drugs of chemotherapy, together with the two standard anti-her2 targets, are lost together. In six to eight cycles, of course, there’s a regular evaluation of the results during the input process. The key to the evaluation is to focus on the target, which, of course, we haven’t removed, our breasts’ stoves or lymph nodes, etc. After Sanyang’s new auxiliary, after chemotherapy, we can actually get to this stage of surgery. And our target is against him. Because the target is gonna take us a year. Well, so basically, two weeks after the end of our last chemotherapy, we’ll probably have a schedule for our surgery.
When we’re done with the operation, we can provide a few points to guide our follow-up. That is one of the main reasons why he is new, and that is the same. I’m sure you’ll see an MP grade before me. It’s very similar to triple-negative breast cancer. So, what do we do before treatment with the puncture tumor, what happens after the combination of this new assisted chemotherapy and the extent of its dissipation? And that’s why it makes sense to be new. What makes him meaningful for being new or single-positive? Just because we can compare and know our follow-up programme. It is its contrasting MP ranking that may lead to a slightly different follow-up programme. So this is one of the more important grounds for our new support. So, again, when we’re done with the surgery, we have an M, T, a pathology level. One of the main reasons is that, after we’re done with the surgery, there’s an MP grade, a pathology grade, and what’s the difference with my tumor? If it’s level five, it’s our previous chemotherapy. And it worked very well. It worked very well. So, after the rest of the operation is over, we’ll continue to use the HP double target we used before the new help. This year, at the same time, there’s an endocrinic treatment. Because I just mentioned Sanyang. Our methods were all for this blighting mutation, and it’s time for anti-smoking targeting and endocrinotherapy to be used together. At that time, both of them had a lighter side effect, and they were perfectly able to reconcile. Use it together, not while we were in chemotherapy, but before the endocrine. That’s when we’re going to have an endocrinic incubation while we’re on a target for a long time. Based on your menstruation, a state of the body, etc., the human spirit program and the corresponding difference, whether it’s a mosaic or an al class, etc. Before menopause is after menopause. Likewise, are we going to undergo treatment? Depends. The choice of how you operate depends on how you do it. If I choose breast milk during the operation, we might have to do another treatment this time before the target. Once the treatment is over, the slow target is added to the endocrine. What if it’s a complete or a pathological condition, without the lymphoma transfer of the armpits and without the need for treatment, as I just said, it’s gonna take a year to target, the endocrin continues to eat, the endocrinic is the longest line, the endocrinic is a drug, and we’re gonna take 5-7 years. Some younger girls eat, not for 10 years, and this is the Sanyang luxurious set.
